Ermium presentation at the 19th World Congress of Basic and Clinical Pharmacology held in Glasgow further show the promise of Ermium compounds for SLE and other auto-immune disease indications.
July 6, 2023
Ermium Therapeutics strengthens its management team with the appointment of Dr Gerhard Müller as Head of Medicinal Chemistry
Gerhard has a striking track record both in drug discovery and entrepreneurship. Throughout his career, Gerhard has worked on a wide range of different target classes in numerous disease areas. Gerhard’s expert knowledge in medicinal chemistry allowed him to establish novel design paradigms, proven by over 75 peer-reviewed publications and involvement of projects that translated into DC. He recently co-founded Anavo Therapeutics and prior to that he co-founded Gotham Therapeutics. Besides that, Gerhard has hold key positions at Mercachem, GPC Biotech, Axxima Pharmaceuticals, Glaxo, Bayer, and Organon.
Gerhard received his PhD in organic chemistry from the Technical University of Munich, where he worked with Prof. Dr. Horst Kessler on anti-adhesive integrin antagonists.
Ermium management team is growing with the appointment of Stéphane Durant des Aulnois as CFO. Stéphane is bringing a wide experience in terms of positions in finance and investor relationship, and more recently in business development.
Prior to joining Ermium Therapeutics, Stéphane Durant des Aulnois served as Chief Financial Officer & Head of Alliances and Business development at Lysogene, a phase 3 gene therapy company listed on Euronext, where he successfully led capital raising activities and closed the acquisition of two assets. Previously, Stéphane spent nine years at Ipsen, first as Vice-President Head of Investor Relations for the Group, then as CFO of Ipsen Iberia, in charge of financial, procurement and supply chain activities. Earlier in his career, he worked in Private Equity at LaSalle Investment management, at Calyon Americas and at Exane BNP Paribas as a sell-side research Analyst. He holds a master’s degree (MSc) in Accounting and Finance from the London School of Economics (LSE) and in Management from Paris Dauphine University. He also holds an Executive Leadership degree from Harvard Business School.
Ermium Therapeutics SAS, a discovery-stage biotechnology company developing innovative therapies for auto-immune diseases, is announcing today the expansion of the Company management team with the appointment of Dr Hélène Asnagli as Head of Biology/Pharmacology.
Dr Asnagli brings strong expertise in non-clinical R&D for auto-immune diseases.
Mr. Main is a highly experienced biopharmaceutical executive who has more than 30 years of industry leadership experience with a strong track record of value creation and company growth.
David is President and Chief Executive Officer of Notch Therapeutics. Previously, as Chairman and CEO of Aquinox Pharmaceuticals, a company he co-founded in 2006, David oversaw the advancement of the company’s lead product from target validation through Phase 3 clinical trials. He also led the transition of Aquinox from a private company to a Nasdaq-listed public company with approximately $300 million raised in equity capital and then completed the successful merger of Aquinox with Neoleukin Therapeutics. Prior to his leadership of Aquinox, David Main served as President and CEO of INEX Pharmaceuticals and as a Vice President of QLT. He formerly served as the Chair of LifeSciences BC (formerly BC Biotech), BIOTECanada, and Accel-Rx as well as a Director of BIO.org. David began his career as a licensed pharmacist at the Royal Columbian Hospital in New Westminster, B.C. He received a BSc in pharmacy and an MBA from the University of British Columbia.
Ermium Therapeutics SAS, a discovery-stage biotechnology company developing innovative therapies for auto-immune diseases, is announcing today that Dr Annegret Van der Aa, CSO/CDO will be presenting promising preclinical data on Ermium immunomodulators for the treatment of systemic lupus erythematosus (SLE) and other type I interferon-driven diseases at the ACR Convergence 2022 conference to be held between November 10th – 14th in Philadelphia, US, and virtually.
Ermium is honored to pitch as a presenting company and also participate to a “Therapeutic Session: Autoimmune and Inflammatory Diseases” at the Sachs Associates 22nd annual Biotech In Europe Forum held in Basel, on 21st and 22nd of September 22.
Dr Annegret Van der Aa (CSO – CDO), Dr Kristof Van Emelen (Head of Medicinal Chemistry) and Dr Jean-Philip Herbeuval (Scientific founder) are co-author of “CXCR4 as a novel target in immunology: moving away from typical antagonists” published online in Future Drug Discovery (vol 4, n°2) – see link. This publication is at the cornerstone of Ermium CXCR4-specific immunomodulators and their uses in auto-immune diseases. It gathers scientists from Université Paris Cité, CNRS, University of Glasgow, and Ermium Therapeutics.
Ermium Therapeutics © 2023 All Rights Reserved
Design by Cédric Adam
